glp-1 news 2025 november Receptor Agonist Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 November in review: GLP-1 breakthroughs,

GLP-1 is an incretin hormone secreted by the intestine after food intake

You may be a candidate for GLP-1 medication if you have a BMI in the overweight or obese range, or if you have a condition called insulin resistance

Consequently, further investigation is warranted [29]

The FXR-activating function of GLP-1RAs also helps protect the gut barrier (Sorribas et al., 2019)

As GLP-1RAs can suppress thirst, patients should be counselled to maintain fluid intake to prevent dehydration and acute kidney injury

Youll know whether you tolerate these medications well, how much appetite suppression you experience, and what kind of weight loss pace to expect